[1] 张智海,刘忠厚,李娜,等.中国人骨质疏松症诊断标准专家共识(第三稿•2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010.[2] Tabatabaei-Malazy O, Salari P, Khashayar P, et al. New horizons in treatment of osteoporosis. Daru. 2017;25(1):2. [3] 周建烈,刘忠厚.补充钙和维生素D防治骨质疏松症的全球临床指南进展[J].中国骨质疏松杂志,2017,23(03):371-380.[4] 黄和涛,潘建科,刘军,等.骨质疏松症用药规律研究[J].中医学报, 2017,32(1):124-126.[5] 司誉豪,郭杨,马勇.骨质疏松症靶向治疗的研究进展[J].中国骨质疏松杂志,2016,22(7):923-928.[6] 帅婷,田旭,王新田,等.冲突性Meta分析评价方法:Jadad法则简介[J].中国循证医学杂志,2016,16(4):492-496.[7] 应小柏,涂琦.注射用骨肽联合阿仑膦酸钠片治疗原发性骨质疏松症的疗效观察[J].中国医院用药评价与分析, 2017,17(11): 1484-1485+1488.[8] 施鹏旭,李玥婷,华凯,等.注射用骨肽与阿仑膦酸钠用于骨质疏松症患者治疗中的临床效果[J].中国实用医药, 2017,12(4): 105-106.[9] 廖化波,张俊娟.阿仑膦酸钠联合骨肽治疗骨质疏松症患者的临床效果[J].中国骨质疏松杂志,2017,23(6):784-786.[10] 刘懿锋.阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的临床效果分析[J].当代医学,2016,22(32):148-149.[11] 赵爱玲.阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的疗效观察[J].北方药学,2015,12(1):78-79.[12] 武永华.阿仑膦酸钠片联合骨肽片治疗骨质疏松症伴疼痛的临床研究[J].中外医疗,2015,34(29):120-121.[13] 程勇.阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的临床效果分析[J].中国实用医药,2015,10(24):124-126.[14] 于建红.注射用骨肽联合阿仑膦酸钠治疗骨质疏松症的临床疗效观察[J].中国医药指南,2015,13(23):40+42.[15] 陈顺兴,陈福友.注射用骨肽联合阿仑膦酸钠治疗骨质疏松症的临床疗效[J].中国现代药物应用,2015,9(15):16-18.[16] 张福华.阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的临床效果[J].社区医学杂志,2015,13(12):79-80.[17] 梁碧彦,钟伟湘,李尚,等.评价阿仑膦酸钠联合注射用骨肽及碳酸钙D_3片治疗骨质疏松症的疗效及安全性[J].中国现代药物应用, 2015,9(09):112-113.[18] 雷景辉.注射用骨肽联合阿仑膦酸钠治疗骨质疏松症效果观察[J].慢性病学杂志,2014,15(2):129-130.[19] 黄建民.阿仑膦酸钠联合注射用骨肽治疗骨质疏松症的疗效观察[J].广东医学,2010,31(16):2159-2160.[20] Harvey NC, McCloskey EV, Mitchell PJ, et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. 2017;28(5):1507-1529. [21] 马思思,王娟秀,何文霜,徐策,黄承钰,阴文娅.中老年居民骨质疏松症影响因素分析[J].中国公共卫生,2016,32(5):650-653.[22] Cano A, Chedraui P, Goulis DG, et al. Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas. 2018;107:7-12. [23] 原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-444.[24] Armstrong JJ, Rodrigues IB, Wasiuta T, et al. Quality assessment of osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal. Arch Osteoporos. 2016 ; 11(1):6. [25] Wu J, Zhang Q, Yan G, et al. Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J Orthop Surg Res. 2018; 13(1):194. [26] Mederle OA, Balas M, Ioanoviciu SD, et al. Correlations between bone turnover markers, serum magnesium and bone mass density in postmenopausal osteoporosis. Clin Interv Aging. 2018;13:1383-1389. [27] Ma X, Xu Z, Ding S, et al. Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-β/signal transducer and activator of transcription 1 pathway. Exp Ther Med. 2018; 15(1):182-190. [28] Sun K, Wang J, Liu F, et al. Ossotide promotes cell differentiation of human osteoblasts from osteogenesis imperfecta patients by up-regulating miR-145. Biomed Pharmacother. 2016;83:1105-1110. [29] 姜溪,陈芙蓉,任雷鸣,等.注射用复方骨肽的药效学及其作用机制研究[J].现代药物与临床,2017,32(6):961-966.[30] Calvo-Guirado JL, Gómez-Moreno G, Delgado-Ruiz RA, et al. Clinical and radiographic evaluation of osseotite-expanded platform implants related to crestal bone loss: a 10-year study. Clin Oral Implants Res. 2014;25(3):352-358. |